122 related articles for article (PubMed ID: 7503662)
1. The diagnostic value of thrombomodulin immunolocalization in serous effusions.
Ascoli V; Scalzo CC; Taccogna S; Nardi F
Arch Pathol Lab Med; 1995 Dec; 119(12):1136-40. PubMed ID: 7503662
[TBL] [Abstract][Full Text] [Related]
2. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
3. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
4. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry.
Tickman RJ; Cohen C; Varma VA; Fekete PS; DeRose PB
Acta Cytol; 1990; 34(4):491-6. PubMed ID: 2197840
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
7. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
Delahaye M; Hoogsteden HC; Van der Kwast TH
J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
[TBL] [Abstract][Full Text] [Related]
9. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations.
Wieczorek TJ; Krane JF
Cancer; 2000 Oct; 90(5):312-9. PubMed ID: 11038429
[TBL] [Abstract][Full Text] [Related]
12. Heparanase expression: a potential ancillary diagnostic tool for distinguishing between malignant cells and reactive mesothelium in body cavity effusions.
Doviner V; Maly B; Reinhartz T; Vlodavsky I; Sherman Y
Cytopathology; 2007 Feb; 18(1):13-9. PubMed ID: 17250598
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of p53 protein in the study of serous effusions.
Zoppi JA; Pellicer EM; Sundblad AS
Acta Cytol; 1995; 39(4):721-4. PubMed ID: 7631546
[TBL] [Abstract][Full Text] [Related]
14. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
Mezger J; Lamerz R; Permanetter W
J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations.
Hecht JL; Pinkus JL; Pinkus GS
Cancer; 2006 Feb; 108(1):56-9. PubMed ID: 16329115
[TBL] [Abstract][Full Text] [Related]
17. A new epithelial membrane antigen (Calam 27) as a marker of carcinoma in serous effusions.
Gioanni J; Caldani C; Zanghellini E; Mazeau C; Duplay H; Ferrua B; Schneider M
Acta Cytol; 1991; 35(3):315-9. PubMed ID: 2042433
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
Duggan MA; Masters CB; Alexander F
Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
20. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]